Rein Therapeutics stock forecast
Want to see RNTX full AI Analyst Report?
Rein Therapeutics (RNTX) Stock Forecast & Price Target
RNTX Analyst Ratings
RNTX Stock 12 Month Forecast
Average Price Target
$6.00▲(971.43% Upside)Detailed List of Analyst Forecasts​
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Jason McCarthy | Maxim Group | $4 | buy | 614.29%Upside | Reiterated | 10/22/26 | ||
| Brandon Folkes | H.C. Wainwright | $8 | buy | 1328.57%Upside | Reiterated | 09/21/26 | ||
| Kemp Dolliver | Brookline Capital Markets | ― | hold | ― | Downgraded | 01/21/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Jason McCarthyMaxim Group | BuyReiterated$4 | 10/22/26 | 614.29%Upside | ||
| Brandon FolkesH.C. Wainwright | BuyReiterated$8 | 09/21/26 | 1328.57%Upside | ||
| Kemp DolliverBrookline Capital Markets | HoldDowngraded | 01/21/26 | ― |
Best Analysts Covering Rein Therapeutics
Copying Brandon Folkes's trades and holding each position for 3 Months would result in 25.00% of your transactions generating a profit, with an average return of -8.56% per trade.
Copying Brandon Folkes's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -39.19% per trade.
Copying Brandon Folkes's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -45.66% per trade.
RNTX Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 2 | 6 | 6 | 6 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 2 | 6 | 6 | 6 | 2 |
In the current month, RNTX has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. RNTX average Analyst price target in the past 3 months is 6.00.
RNTX Financial Forecast
RNTX Sales Forecast
Next quarter’s sales forecast for RNTX is $0 with a range of ― to ―. The previous quarter’s sales results were $0. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
